BioSpace News Archive

Harvard scientists believe they’ve uncovered one of the primary drivers of aging, and it isn’t DNA mutation. A study published Thursday points to epigenetics as the key.

The FDA approved Novo Nordisk’s Rybelsus as a first-line treatment option for adults with type 2 diabetes, signaling a shift from its previous indication as a second-line approach.

The past decade has seen an immuno-oncology revolution, but there is still work to be done. BioSpace looks at innovative research from Nectin Therapeutics, Compugen and Biond Biologics.

Cambrian Biopharma announced that its latest pipeline company, Isterian Biotech, has emerged from stealth to develop first-in-class medicines to tackle aging.

Pie Medical Imaging (“PMI”), a global leader in cardiac imaging, today launched CAAS Qardia 2.0, a new version of their innovative echocardiography software platform.

Seres Therapeutics, Inc. (Nasdaq: MCRB) (“Seres” or the “Company”), a leading microbiome therapeutics company, today announced that on January 11, 2023, the Compensation and Talent Committee of Seres’ board of directors granted inducement equity grants covering an aggregate of 13,500 shares of its common stock to five new employees.

Forefront Collaborative, an ACCME-accredited independent healthcare education company, in partnership with MadMicrobe Studios and Vectorform, is proud to announce the next chapter for its ImmerseRX augmented reality (AR) app: a metastatic non-small cell lung cancer (mNSCLC) immersive learning experience.

As part of its commitment to offering the most advanced technology for cancer treatment, the Cancer Institute at Tampa General Hospital announced that it is expanding its Radiation Oncology program to include the addition of new cancer treatment technology and enhanced locations under the direction of world-renowned physicians.

First Wave BioPharma, Inc. announced that the U.S. Food and Drug Administration is reviewing the Investigational New Drug amendment for the planned Phase 2 clinical trial of an enhanced enteric microgranule delivery formulation for adrulipase as a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis as an IND protocol amendment.

Lipogems, a clinical stage- global medical technology company, announces the first patient enrolled on January 13, 2023, in the ARISE U.S. FDA IDE study, which aims to examine MicroFat versus corticosteroid injection for the treatment of Knee Osteoarthritis (OA).